Ravindran Menon, D.; Li, Y.; Yamauchi, T.; Osborne, D.G.; Vaddi, P.K.; Wempe, M.F.; Zhai, Z.; Fujita, M.
EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses. Pharmaceuticals 2021, 14, 1081.
https://doi.org/10.3390/ph14111081
AMA Style
Ravindran Menon D, Li Y, Yamauchi T, Osborne DG, Vaddi PK, Wempe MF, Zhai Z, Fujita M.
EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses. Pharmaceuticals. 2021; 14(11):1081.
https://doi.org/10.3390/ph14111081
Chicago/Turabian Style
Ravindran Menon, Dinoop, Yang Li, Takeshi Yamauchi, Douglas Grant Osborne, Prasanna Kumar Vaddi, Michael F Wempe, Zili Zhai, and Mayumi Fujita.
2021. "EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses" Pharmaceuticals 14, no. 11: 1081.
https://doi.org/10.3390/ph14111081
APA Style
Ravindran Menon, D., Li, Y., Yamauchi, T., Osborne, D. G., Vaddi, P. K., Wempe, M. F., Zhai, Z., & Fujita, M.
(2021). EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses. Pharmaceuticals, 14(11), 1081.
https://doi.org/10.3390/ph14111081